• Immunome, Inc. recently reported a lower full-year net loss for 2025, updated investors on progress in its oncology pipeline, and filed a US$156.03 million common stock shelf registration tied to an ESOP-related offering.

• A key angle for investors is how reduced losses alongside an expanded late-stage cancer portfolio and potential future equity issuance could shape Immunome’s financial and operational flexibility.

• Next, we will examine how Immunome’s reduced net loss and plans to file a New Drug Application influence its broader investment narrative.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

To own Immunome, you have to be comfortable backing a high-risk oncology platform where value largely hinges on execution around varegacestat and the broader late-stage pipeline, rather than current fundamentals. The latest results show a narrower full-year net loss of US$212.39 million and lower loss per share, which slightly eases the burn profile but does not change the fact that the company remains deeply unprofitable. The planned New Drug Application for varegacestat and multiple solid tumor INDs are still the key near-term catalysts, and the positive Phase 3 data keep that story intact. What does shift the balance a bit is the US$156.03 million common stock shelf and new option grants, which reinforce equity dilution and ownership overhang as central risks alongside clinical and regulatory uncertainty.

However, the prospect of further dilution is not something investors can ignore. Despite retreating, Immunome’s shares might still be trading above their fair value and there could be some more downside. Discover how much.

Three Simply Wall St Community fair value estimates span roughly US$29 to over US$215 per share, showing just how far apart individual views can be. Set against this wide dispersion, the recent shelf registration and ongoing losses highlight why some market participants may focus more on funding risk while others concentrate on pipeline milestones and potential value creation, encouraging you to weigh several contrasting viewpoints before deciding how Immunome fits your portfolio.

Explore 3 other fair value estimates on Immunome – why the stock might be worth over 10x more than the current price!

Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.

• A great starting point for your Immunome research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

• Our free Immunome research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Immunome’s overall financial health at a glance.